CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders - Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study.
Psychiatry research May 1, 2023 Kirsten R Müller-vahl, Anna Pisarenko, Natalia Szejko et al. 36 citations
A randomized, placebo-controlled phase IIIb trial tested the cannabis extract nabiximols in 97 adults with Tourette syndrome or chronic tic disorders. Although 21.9% of those receiving nabiximols achieved a 25% or greater reduction in tics compared to 9.1% on placebo, the difference was not statistically significant. Secondary analyses showed trends toward improvement in tics, depression, and quality of life. Exploratory subgroup analyses suggested that males, patients with more severe tics, and those with comorbid ADHD may benefit more. No major safety concerns arose.